Last reviewed · How we verify

Vegf Trap (AFLIBERCEPT)

Regeneron · FDA-approved approved Recombinant protein Quality 55/100

Aflibercept, also known as Vegf Trap, is a vascular endothelial growth factor inhibitor developed by Regeneron Pharmaceuticals. It works by binding to vascular endothelial growth factor A, preventing its interaction with its receptor and thereby inhibiting angiogenesis. Aflibercept is approved to treat various eye conditions, including macular edema and age-related macular degeneration, as well as metastatic colorectal cancer. It is a small molecule drug that has been commercially available since 2011. Key safety considerations include potential increased risk of hypertension, proteinuria, and gastrointestinal perforation.

At a glance

Generic nameAFLIBERCEPT
SponsorRegeneron
Drug classVascular Endothelial Growth Factor Inhibitor
TargetVascular endothelial growth factor A
ModalityRecombinant protein
Therapeutic areaOncology
PhaseFDA-approved
First approval2011
Annual revenue9800

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: